Cardiff Oncology ( CRDF ) has been an interesting story to watch unfold. In particular, 2025 was momentous after seeing the first readout of their randomized, phase 2 trial in first-line colorectal cancer, leading to aI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfall ...